Our mission is to transform gene therapy for human liver diseases.

sAAVient Therapeutics was established in 2023. Our founders have more than 75 cumulative years of experience and hold 11 patents for innovations in the area of AAV vector development.

AAV3 is the most efficient vector with a remarkably selective human liver-tropism. sAAVient Therapeutics has developed capsid-modified NextGen AAV3 vectors that are up to 15-fold more efficient in transducing human liver cells. We've also developed genome-modified GenY vectors that are up to 10-fold more efficient in mediating transgene expression. NextGen AAV3 vectors are ready for testing in clinical trials.

Timeline